lipodystrophy comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-26. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
=== Legal status === On 17 September 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for melphalan. The applicant for this medicinal product is Adienne S.r.l. S.U. Melphalan was approved for medical use in the European Union in November 2020.
== Crystal structure == Serotonin crystallizes in P212121 chiral space group forming different hydrogen-bonding interactions between serotonin molecules via N-H...O and O-H...N intermolecular bonds. Serotonin also forms several salts, including pharmaceutical formulation of serotonin adipate.
== Breeding == Potatoes, both S. tuberosum and most of its wild relatives, are self-incompatible: they bear no useful fruit when self-pollinated. This trait is problematic for crop breeding, as all sexually produced plants must be hybrids. The gene responsible for self-incompatibility, as well as mutations to disable it, are now known. Self-compatibility has successfully been introduced both to diploid potatoes (including a special line of S. tuberosum) by CRISPR-Cas9. Plants having a 'Sli' gene produce pollen which is compatible to its own parent and plants with similar S genes. This gene was cloned by Wageningen University and Solynta in 2021, which would allow for faster and more focused breeding. Diploid hybrid potato breeding is a recent area of potato genetics supported by the finding that simultaneous homozygosity and fixation of donor alleles is possible. Wild potato species useful for breeding blight resistance include Solanum desmissum and S. stoloniferum, among others.
Sources: en.wikipedia.org
== Occurrence == Obsidian is found near volcanoes in locations which have undergone rhyolitic eruptions. It can be found in Argentina, Armenia, Azerbaijan, Australia, Canada, Chile, Georgia, Ecuador, El Salvador, Greece, Guatemala, Hungary, Iceland, Indonesia, Italy, Japan, Kenya, Mexico, New Zealand, Papua New Guinea, Peru, Russia, Scotland, the Canary Islands, Turkey and the United States. Obsidian flows which are so large that they can be hiked on are found within the calderas of Newberry Volcano (Big Obsidian Flow, 700 acres) and Medicine Lake Volcano in the Cascade Range of western North America, and at Inyo Craters east of the Sierra Nevada in California. Yellowstone National Park has a mountainside containing obsidian located between Mammoth Hot Springs and the Norris Geyser Basin, and deposits can be found in many other western U.S. states including Arizona, Colorado, New Mexico, Texas, Utah, and Washington, Oregon and Idaho.
=== Neurodegenerative diseases and mental disorders === Scientists are investigating the role of dysregulation of this pathway in aging, neurodegenerative diseases, mental disorders, somatic symptom disorders, and chronic fatigue syndrome (CFS).
Somalia's foreign relations are handled by the President as the head of state, the Prime Minister as the head of government, and the federal Ministry of Foreign Affairs. According to Article 54 of the national constitution, the allocation of powers and resources between the Federal Government and the Federal Republic of Somalia's constituent Federal Member States shall be negotiated and agreed upon by the Federal Government and the Federal Member States, except in matters pertaining to foreign affairs, national defence, citizenship and immigration, and monetary policy. Article 53 also stipulates that the Federal Government shall consult the Federal Member States on major issues related to international agreements, including negotiations vis-a-vis foreign trade, finance and treaties. The Federal Government maintains bilateral relations with a number of other central governments in the international community. Among these are Djibouti, Ethiopia, Egypt, the United Arab Emirates, Yemen, Turkey, Italy, the United Kingdom, Denmark, France, the United States, the People's Republic of China, Japan, Russian Federation and South Korea. Additionally, Somalia has several diplomatic missions abroad. There are likewise various foreign embassies and consulates based in the capital Mogadishu and elsewhere in the country. Somalia is also a member of many international organisations, such as the United Nations, African Union and Arab League. It was a founding member of the Organisation of Islamic Cooperation in 1969.
Sources: en.wikipedia.org
In August 2019, BASF agreed to sell its global pigments business to Japanese fine chemical company DIC for €1.15 billion ($1.28 billion) on a cash and debt-free basis. In September 2019, BASF signed an agreement with DuPont Safety & Construction, a subsidiary business unit of DuPont, to sell its ultrafiltration membrane business, Inge GmbH. According to BASF executives, Inge GmbH and its products fit better with DuPont and their business strategy. In February 2023, BASF announced that the company is planning to close one of its two ammonia factories at its site in Ludwigshafen, this comes as part of the companies plans to cut costs as the organisation has struggled with high energy costs. The result of the organisations plans will lead to increased production in China while resulting in the loss of 2,600 jobs. The Zhanjiang plant extends over 400 hectares and serves mainly the electronic industry and the automotive industry. In September 2023 BASF broke ground on its Zhanjiang syngas plant; the plant was due to be commissioned by 2025. In November 2023 the firm closed a $5bn 15-year investment deal in China, with Chinese banks. As of April 2023, BASF had 30 production facilities in China. CEO Martin Brudermüller held that Chinese revenue is essential to grow his European business in the face of "Europe’s high energy costs and stringent environmental rules."
==== 1.G Viral fusion pores ==== 1.G.1 The Viral Pore-forming Membrane Fusion Protein-1 (VMFP1) Family 1.G.2 The Viral Pore-forming Membrane Fusion Protein-2 (VMFP2) Family 1.G.3 The Viral Pore-forming Membrane Fusion Protein-3 (VMFP3) Family 1.G.4 The Viral Pore-forming Membrane Fusion Protein-4 (VMFP4) Family 1.G.5 The Viral Pore-forming Membrane Fusion Protein-5 (VMFP5) Family 1.G.6 The Hepadnaviral S Fusion Protein (HBV-S Protein) Family 1.G.7 The Reovirus FAST Fusion Protein (R-FAST) Family 1.G.8 The Arenavirus Fusion Protein (AV-FP) Family 1.G.9 The Syncytin (Syncytin) Family 1.G.10 The Herpes Simplex Virus Membrane Fusion Complex (HSV-MFC) Family 1.G.11 Poxvirus Cell Entry Protein Complex (PEP-C) Family 1.G.12 The Avian Leukosis Virus gp95 Fusion Protein (ALV-gp95) Family 1.G.13 The Orthoreovirus Fusion-associated Small Transmembrane (FAST) Family 1.G.14 The Influenza Virus Hemagglutinin/Fusion Pore-forming Protein (Influenza-H/FPP) Family 1.G.15 The Autographa californica Nuclear Polyhedrosis Virus Major Envelope Glycoprotein GP64 (GP64) Family 1.G.16 The Human Immunodeficiency Virus Type 1 (HIV-1) Fusion Peptide (HIV-FP) Family 1.G.17 The Bovine Leukemia Virus Envelop Glycoprotein (BLV-Env) Family 1.G.18 The SARS-CoV Fusion Peptide in the Spike Glycoprotein Precursor (SARS-FP) Family 1.G.19 The Rotavirus Pore-forming Membrane Fusion Complex (Rotavirus MFC) Family 1.G.20 The Hantavirus Gc Envelope Fusion Glycoprotein (Gc-EFG) Family 1.G.21 The Epstein Barr Virus (Human Herpes Virus 4) Gp42 (Gp42) Family 1.G.22 The Cytomegalovirus (Human Herpesvirus 5) Glycoprotein gO (gO) Family
== External links == NPR2+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Invertebrates constitute a vast array of living organisms ranging from the simplest unicellular eukaryotes such as Paramecium to such complex multicellular animals as the octopus, lobster and dragonfly. They constitute about 95% of the animal species. By definition, none of these creatures has a backbone. The cells of single-cell protozoans have the same basic structure as those of multicellular animals but some parts are specialized into the equivalent of tissues and organs. Locomotion is often provided by cilia or flagella or may proceed via the advance of pseudopodia, food may be gathered by phagocytosis, energy needs may be supplied by photosynthesis and the cell may be supported by an endoskeleton or an exoskeleton. Some protozoans can form multicellular colonies. Metazoans are a multicellular organism, with different groups of cells serving different functions. The most basic types of metazoan tissues are epithelium and connective tissue, both of which are present in nearly all invertebrates. The outer surface of the epidermis is normally formed of epithelial cells and secretes an extracellular matrix which provides support to the organism. An endoskeleton derived from the mesoderm is present in echinoderms, sponges and some cephalopods. Exoskeletons are derived from the epidermis and is composed of chitin in arthropods (insects, spiders, ticks, shrimps, crabs, lobsters). Calcium carbonate constitutes the shells of molluscs, brachiopods and some tube-building polychaete worms and silica forms the exoskeleton of the microscopic diatoms and radiolaria.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.